Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Melanoma 44Hodgkin Disease 8Neoplasm Metastasis 6Neoplasms 5Leiomyosarcoma 5Skin Neoplasms 4Lymphoma 4Uveal Melanoma 3Sarcoma 3Hematologic Diseases 2Solid Tumor 1Skin Diseases 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Melanoma, Cutaneous Malignant 1Melanoma Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lung Neoplasms 1Liposarcoma 1Kidney Neoplasms 1Colonic Neoplasms 1Carcinoma 1Breast Neoplasms 1Advanced Melanoma 1

Interventions

Brentuximab Vedotin 20Rituximab 10pirtobrutinib 7dacetuzumab 7Doxorubicin 6ruxolitinib 5Vincristine 5Prednisone 5Lenalidomide 5Cyclophosphamide 5ponatinib 4Imatinib Mesylate 4Dexamethasone 4Bendamustine Hydrochloride 4Azacitidine 4nilotinib 3lintuzumab 3Bortezomib 3vosaroxin 2venetoclax 2spartalizumab 2pomalidomide 2ibrutinib 2Rifampin 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2KW-2478 2Ifosfamide 2Gemcitabine 2Etoposide 2Dacarbazine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Hematologic Diseases × Dacarbazine × Clear all
NCT01716806 2024-06-11

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Seagen Inc.

Phase 2 Completed
131 enrolled 28 charts
Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Peripheral

NCT01060904 2014-12-18

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Seagen Inc.

Phase 1 Completed
51 enrolled
Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡